Overview
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 3 of 6 financial statements were filed late (the longest delay 399 days for 2021).
- 2025not filed
- 202410/04/2026
- 202311/06/2024
- 202225/08/2023
- 202118/08/2023
- 202026/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Trademarks
Napiferyn Biotech holds 3 active trademarks registered with the Polish Patent Office. The first mark was filed in 2017.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| RAPTEIN(word) | Z.519207 | 1 | Protected | Oct 2, 2030 | |
| NAPIFERYN(word) | Z.472073 | 1 | Protected | May 24, 2027 | |
| NAPIFERYN BIOTECH | Z.472075 | 1 | Protected | May 24, 2027 |
| Mark | Protected until | |
|---|---|---|
| RAPTEIN(word) | Oct 2, 2030 | |
| NAPIFERYN(word) | May 24, 2027 | |
| NAPIFERYN BIOTECH | May 24, 2027 |
Authorized Representatives
Manner of representation
The following will be authorized to submit declarations of will on behalf of the company and to represent it: in the case of a one-person management board, the President of the Management Board acting independently; in the case of a multi-member management board: (i) the President of the Management Board acting jointly with the Vice-President or another member of the management board, (ii) the Vice-President acting jointly with the President of the Management Board or another member of the management board, (iii) each other member of the management board may represent the company by acting jointly with the President of the Management Board or the Vice-President.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 768 | $10,372.77 | 48.9796% | |
Magdalena Kozłowskaage 43 | 160 | $2,160.99 | 10.2041% |
Piotr Wnukowskiage 69 | 640 | $8,643.98 | 40.8163% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2014-11-10.
Debt
3 active proceedings recorded in KRZ.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Dec 10, 2025 | Remedial proceedings | In progress | |
| Mar 3, 2025 | Petition to declare entrepreneur bankruptcy | Closed | |
| Jan 22, 2025 | Petition to open remedial proceedings | Closed |
Public aid
10 public aid cases recorded, with a total value of $1,159,293.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 14, 2023 | Aid for research and development projects: industrial research | $900.6K$900,590 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Aug 14, 2023 | Aid for research and development projects: experimental development | $188.9K$188,908 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,857$4,857 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
6 projects recorded: 2 from FE lists ($2,856,613) and 4 Commission grants (FTS) ($2,500,913).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2023-05-01 | 101081974 - Helex - use of extremophile helianthus species to mitigate climate change impact on feedstock and ecosystem services provided by sunflower | $137.8K$137,838 | 1.0.11 - Horizon Europe | |
| 2022-09-01 | 101059632 - Giant leaps - gap resolution in safety, nutritional, allergenicity and environmental assessments to promote alternative protein utilization and the dietary shift | $63,074$63,074 | 1.0.11 - Horizon Europe | |
| 2019-10-01 | 858543 - Alseos - technology to turn waste from rapeseed oil production into valuable food protein. | $2.2M$2,244,512 | 1.1.31 - Horizon 2020 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Proteon PharmaceuticalsS.A. | $2,026,826.52 | proteonpharmaspolkaakcyjna.pl | ||
| Centrum Badań Weterynaryjnych Vetcomplexsp. z o.o. | $255,522.81 | vetcomplex.pl | ||
| UveraS.A. | $155,384.29 | uvera.eu | ||
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| Microbe Plussp. z o.o. | $104,197.26 | microbe-plus.com | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Xenstatssp. z o.o. | $66,774.27 | xenstats.com | ||
| Luna Laboratorysp. z o.o. | $61,894.23 | lunalab.pl |
Change history
| Date | Event | |
|---|---|---|
| 2017-06-20 | Share capital change (71,400.00 PLN → 78,400.00 PLN) | |
| 2017-03-27 | Share capital change (58,400.00 PLN → 71,400.00 PLN) | |
| 2016-09-23 | Share capital change (55,000.00 PLN → 58,400.00 PLN) | |
| 2016-01-22 | Address change (Ul. Dowborczyków 30/34, 90-019, Łódź → Ul. Stanisława Dubois 114/116, 93-465, Łódź) | |
| 2016-01-22 | Share capital change (40,000.00 PLN → 55,000.00 PLN) |
FAQ
Last updated: 2026-07-09